Brought to you by 
Janssen to use Ichor's TriGrid for HBV vaccine delivery
01 Feb 2023
Executive Summary
Janssen Pharmaceuticals Inc. will use Ichor Medical Systems Inc.’s TriGrid electroporation technology as a delivery vehicle for its own DNA-based vaccines for chronic hepatitis B.
Deal Industry
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Drug Delivery
- Macromolecule
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Janssen to use Ichor's TriGrid for HBV vaccine delivery
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice